SAN
DIEGO, Sept. 8, 2022 /PRNewswire/ -- Kintara
Therapeutics, Inc.(Nasdaq: KTRA) ("Kintara" or the "Company"), a
biopharmaceutical company focused on the development of new solid
tumor cancer therapies, today announced that three posters have
been accepted for data presentation at the 2022 Society for
Neuro-Oncology (SNO) Annual Meeting. The 2022 SNO Annual Meeting
will be held from November 16 through
November 20, 2022 in Tampa,
Florida.
Data Presentations:
Phase 2 Study of VAL-083 and Radiotherapy in Newly-Diagnosed,
MGMT-unmethylated GBM
Poster Presenter: Zhongping Chen, MD, Ph.D. – Sun Yat-sen University Cancer
Center
(Presentation Time: Friday, November 18, 2022 - 7:30 to 9:30 pm ET)
Recurrent RELA Fusion-Positive Ependymoma Treated with
VAL-083 under Expanded Access: A Case Report
Poster
Presenter: Carlos Kamiya-Matsuoka,
MD – MD Anderson Cancer Center
(Presentation Time:
Friday, November 18, 2022 -
7:30 to 9:30 pm ET)
VAL-083 in Patients with Recurrent Glioblastoma Treated under
Expanded Access Program
Poster Presenter: Carlos Kamiya-Matsuoka, MD – MD Anderson Cancer
Center
(Presentation Time: Friday, November 18, 2022 - 7:30 to 9:30 pm ET)
ABOUT KINTARA
Located in San Diego,
California, Kintara is dedicated to the development of novel
cancer therapies for patients with unmet medical needs. Kintara is
developing two late-stage, Phase 3-ready therapeutics for clear
unmet medical needs with reduced risk development programs. The two
programs are VAL-083 for Glioblastoma Multiforme (GBM) and REM-001
for Cutaneous Metastatic Breast Cancer (CMBC).
VAL-083 is a "first-in-class," small-molecule
chemotherapeutic with a novel mechanism of action that has
demonstrated clinical activity against a range of cancers,
including central nervous system, ovarian and other solid tumors
(e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical
trials sponsored by the National Cancer Institute (NCI). Based on
Kintara's internal research programs and these
prior NCI-sponsored clinical studies, Kintara is
currently advancing VAL-083 in the GBM AGILE study to support the
development and commercialization of VAL-083 in GBM.
Kintara is also advancing its proprietary, late-stage
photodynamic therapy platform that holds promise as a localized
cutaneous, or visceral, tumor treatment as well as in other
potential indications. REM-001 therapy has been previously
studied in four Phase 2/3 clinical trials in patients with CMBC who
had previously received chemotherapy and/or failed radiation
therapy. With clinical efficacy to date of 80% complete responses
of CMBC evaluable lesions, and with an existing robust safety
database of approximately 1,100 patients across multiple
indications, Kintara is advancing the REM-001 CMBC
program to late-stage pivotal testing.
For more information, please visit www.kintara.com or
follow us on Twitter
at @Kintara_Thera, Facebook and LinkedIn.
SAFE HARBOR STATEMENT
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995, including statements regarding the status of the
Company's clinical trials and the GBM AGILE study. Any
forward-looking statements contained herein are based on current
expectations but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the impact of the
COVID-19 pandemic on the Company's operations and clinical trials;
the Company's ability to develop, market and sell products based on
its technology; the expected benefits and efficacy of the Company's
products and technology; the availability of substantial additional
funding for the Company to continue its operations and to conduct
research and development, clinical studies and future product
commercialization; and, the Company's business, research, product
development, regulatory approval, marketing and distribution plans
and strategies. These and other factors are identified and
described in more detail in the Company's filings with the SEC,
including the Company's Annual Report on Form 10-K for the year
ended June 30, 2021, the Company's
Quarterly Reports on Form 10-Q, and the Company's Current Reports
on Form 8-K.
CONTACT: ir@kintara.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kintara-therapeutics-announces-three-abstracts-have-been-accepted-for-the-2022-society-for-neuro-oncology-annual-meeting-301620008.html
SOURCE Kintara Therapeutics